An observational study in Pregnancy Related, Pregnancy and Pregnancy High-risk, sponsored by Janssen Research & Development, LLC. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to find out how often:
Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population are cases reported to the Company global safety database from post-marketing reports of exposure to nipocalimab during pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Documented exposure to least one dose of nipocalimab any time immediately before ( 1 week [7 days ] before estimated date of conception) or during pregnancy in the post-marketing setting
Exclusion Criteria:
Participants with documented exposure to at least one dose of nipocalimab any time immediately before (within 1 week \[7 days\] before estimated date of conception) or during pregnancy in the post-marketing setting. No drug will be administered as a part of this study. Participants received nipocalimab as per their routine clinical practice settings.
Prevalence of Fetal Growth Restriction
A fetus with an estimated fetal weight less than the 10th percentile for gestational age based upon a population reference or standard.
Time frame: During pregnancy (Up to Week 42)
Prevalence of Small for Gestational Age
A newborn with a birthweight less than the 10th percentile for gestational age based upon a population reference or standard.
Time frame: At birth
Prevalence of Hypertensive Disorders of Pregnancy
Hypertensive disorder of pregnancy (that is, preeclampsia, gestational hypertension, hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, or eclampsia).
Time frame: From 20 weeks gestation through 6 weeks postpartum
Prevalence of Placental Abruption
A condition in which the placenta has begun to separate from the uterus before the fetus is born.
Time frame: During pregnancy (Up to Week 42)
Prevalence of Serious Infections in Neonates
Infections resulting in a hospitalization that occur within the first 27 days of life (0-27 days).
Time frame: Birth to 27 days
Prevalence of Serious Infections in Infants
Infections resulting in a hospitalization that occur between 28 and 365 days of life.
Time frame: 28 days to 365 days after birth
Prevalence of Non-chromosomal Major Congenital Malformations
Congenital abnormality that requires medical or surgical treatment, has a serious adverse effect on health and development, or has significant cosmetic impact, excluding those that are chromosomal or Mendelian-inherited anomalies.
Time frame: During pregnancy (up to Week 42) and up to 1 year after birth
Prevalence of Live Birth
Delivery of a live newborn.
Time frame: At Delivery
Prevalence of Spontaneous Abortion
Clinically detected pregnancy loss before 20 completed weeks of gestation that occurs without medical or surgical intervention to terminate the pregnancy.
Time frame: Prior to 20 weeks gestation
Prevalence of Stillbirth
Fetus born dead at \>= 20 weeks gestation or weighing \>= 350 grams. Fetal death occurring \> 20 weeks but less than 28 weeks gestation is considered an early fetal loss. Fetal death occurring \> 28 weeks is considered a late fetal loss. If gestational age is unknown, stillbirth refers to a fetus weighing \>= 350 grams.
Time frame: At or after 20 completed weeks of gestation
Prevalence of Preterm Birth
Delivery of a viable infant before 37 completed weeks of gestation.
Time frame: Prior to 37 completed weeks of gestation
Prevalence of Intrapartum Hemorrhage
Maternal complication characterized by significant blood loss occurring during pregnancy.
Time frame: During pregnancy (Up to 42 weeks)
Prevalence of Postpartum Hemorrhage
Maternal complication characterized by significant blood loss occurring after pregnancy.
Time frame: At Birth and after 12 weeks delivery
Prevalence of Neonatal Death
Death that occurs within the first 27 days of life (0-27 days).
Time frame: Birth to 27 days
Prevalence of Infant Death
Death that occurs between 28 and 365 days of life.
Time frame: 28 days to 365 days after birth
No study locations are listed for this record.
Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.jnj.com
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Apr 2036, 113 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Janssen Research & Development, LLC →